Researchers developed novel method that can target delivery of small volumes of drugs into the lung. [© krishnacreations/Fotolia]
Researchers developed novel method that can target delivery of small volumes of drugs into the lung. [© krishnacreations/Fotolia]

Scientists from Columbia Engineering and Columbia University Medical Center (CUMC) say they have developed a novel technique that can target delivery of small volumes of drugs into the lung. They believe their approach, in which microliters of liquid containing a drug are instilled into the lung, distributed as a thin film in the predetermined region of the lung airway, and absorbed locally, may provide much more effective treatment of lung disease.

The team’s study (“Targeted delivery of liquid microvolumes into the lung”) appears in an online early edition of Proceedings of the National Academy of Sciences.

Lungs are susceptible to many diseases, including cystic fibrosis, bronchopneumonia, chronic obstructive pulmonary disease, and lung cancer, that are currently treated by systemic application of drugs, by oral intake, or aerosol inhalation.

“We envision that our micro-volume liquid instillation approach will enable predictable drug concentrations at the target site, reducing the amount of drug required for effective disease treatment with significantly reduced side effects,” says Gordana Vunjak-Novakovic, Ph.D., Mikati Foundation Professor of Biomedical Engineering and professor of medical sciences (in Medicine), who supervised the work in her lab for stem cells and tissue engineering.

The main challenge for the team was the enormous complexity of the lung structure that provides the vital function of oxygen and carbon dioxide exchange with the blood. Both the tissue architecture and the air flow change dramatically along the 24 generations of the lung airway, from the large bronchus down to the alveoli.

Jinho Kim, Ph.D., a postdoctoral fellow in Dr. Vunjak-Novakovic's lab and the lead author of the study, realized that the distance a liquid plug travels before being absorbed as liquid film can be varied by changing the plug volume and the regime of ventilation. By studying liquid plugs in simple glass tubes, he developed a mathematical model describing liquid transport process in each generation of the airway tree. The model was used to determine the liquid plug volume and the parameters of programmed ventilation for delivery into a specific region of the lung. The model predictions were confirmed by demonstrating targeted liquid film deposition in ventilated lungs, using three different imaging modalities.

“Liquid instillation has been used for providing lung surfactant to the entire lungs in premature infants that cannot produce enough surfactant to breathe normally,” Dr. Kim observes. “Although liquid instillation has great therapeutic potential, its applications have been unexplored, largely because of limited understanding of the liquid transport in the lung airways. We are very excited about the implications of our work.”

He devised the approach for targeted delivery of microvolumes of drugs, developed the necessary theory, and conducted the supporting experiments with John O'Neill, a biomedical engineering Ph.D. student. At CUMC, Matt Bacchetta, M.D., associate professor of surgery, and Valerio Dorrello, M.D., assistant professor of pediatrics, helped define the clinically relevant parameters for drug delivery, and optimize lung ventilation and perfusion. The researchers plan next to demonstrate treatment of lung diseases such as cystic fibrosis and airway infections by delivering pulmonary drugs using their liquid instillation approach.

“We are fascinated by the opportunities that bioengineering approaches offer to more effectively treat lung disease,” adds Dr. Vunjak-Novakovic adds. “The lung is a hugely complex organ that has billions of cells within a hierarchically organized tissue that cannot be built from scratch. Four years ago, we started research of lung regeneration using stem cells and bioengineering methods. And we continue to work with our clinical colleagues to develop new treatment approaches for treating lung disease.”

Previous articleIncyte to Co-Develop Hengrui’s SHR-1210 in Up-to-$795M+ Deal
Next articleHorizon to Advance Redx’s Pan-RAF Inhibitors against Cancer